Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue International Heart Journal Année : 2021

Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance

Résumé

Intravenous mineralocorticoid receptor antagonists (MRAs) have been used in some centers for decades to reduce the risk of hypokalemia and boost diuresis in acutely decompensated heart failure (ADHF). We report the well-tolerated use of intravenous MRAs as a rescue procedure in 3 patients admitted for ADHF with important diuretic resistance. Undertaking trials evaluating the effect of this therapeutic strategy in ADHF could represent a promising avenue.
Fichier principal
Vignette du fichier
Case Canrenoate Girerd.pdf (546.42 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03116131 , version 1 (20-01-2021)

Identifiants

Citer

Nicolas Girerd, Matthieu Aubry, Pierre Lantelme, Olivier Huttin, Patrick Rossignol. Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance. International Heart Journal, 2021, 62 (1), pp.193-196. ⟨10.1536/ihj.20-442⟩. ⟨hal-03116131⟩
73 Consultations
171 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More